SEARCH WITHIN CONTENT
VOLUME 10 , ISSUE 2 ( May-August, 2023 ) > List of Articles
Arijit Kayal, Dipan Saha, Anindya Karmakar, Debarati Bhar, Pranesh Sarkar
Keywords : Acute pancreatitis, Case report, Diabetes mellitus, GLP-1 agonist
Citation Information : Kayal A, Saha D, Karmakar A, Bhar D, Sarkar P. Incretin-based Antidiabetic Therapy and Pancreatitis: A Case Series. Bengal Physician Journal 2023; 10 (2):69-70.
License: CC BY-NC 4.0
Published Online: 07-08-2023
Copyright Statement: Copyright © 2023; The Author(s).
Dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly referred to as gliptins, are a class of oral antihyperglycemic agents used for the management of type 2 diabetes mellitus. They work by inhibiting the enzyme DPP-4, which leads to increased levels of incretin hormones such as glucagon-like peptide-1 (GLP-1). On the contrary, glucagon-like peptide 1 receptor agonists (GLP-1RA) are the newest treatment for diabetes mellitus (DM). Many of these incretin-based agents have shown positive results in their respective cardiovascular outcome trials (CVOT). Acute pancreatitis is a condition that has been a subject of concern in relation to incretin-based therapies, as reported in some randomized clinical trials. Here, we present three such cases of pancreatitis related to this antidiabetic therapy.